A citation-based method for searching scientific literature

Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
Times Cited: 3







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study.
Ionut Bebu, Barbara H Braffett, David Schade, William Sivitz, John I Malone, Rodica Pop-Busui, Gayle M Lorenzi, Pearl Lee, Victoria R Trapani, Amisha Wallia,[...]. Diabetes Care 2020
4
33

Management of diabetes and hyperglycaemia in the hospital.
Francisco J Pasquel, M Cecilia Lansang, Ketan Dhatariya, Guillermo E Umpierrez. Lancet Diabetes Endocrinol 2021
4
33

Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification.
Anoop Misra, Amerta Ghosh, Ritesh Gupta. Diabetes Metab Syndr 2021
8
33

Severe Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease in Patients With Diabetes.
Jamal S Rana, Howard H Moffet, Jennifer Y Liu, Andrew J Karter. Diabetes Care 2021
1
100


Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort.
Neda Rasouli, Naji Younes, Kristina M Utzschneider, Silvio E Inzucchi, Ashok Balasubramanyam, Andrea L Cherrington, Faramarz Ismail-Beigi, Robert M Cohen, Darin E Olson, Ralph A DeFronzo,[...]. Diabetes Care 2021
1
100

Glycemic Control and Risk of Cellulitis.
Galia Zacay, Fabienne Hershkowitz Sikron, Anthony D Heymann. Diabetes Care 2021
3
33

Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses.
Natalie Nanayakkara, Andrea J Curtis, Stephane Heritier, Adelle M Gadowski, Meda E Pavkov, Timothy Kenealy, David R Owens, Rebecca L Thomas, Soon Song, Jencia Wong,[...]. Diabetologia 2021
10
33

Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms.
Naveed Sattar, Iain B McInnes, John J V McMurray. Circulation 2020
253
33


Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33


Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
30
33

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
Yue Fei, Man-Fung Tsoi, Bernard Man Yung Cheung. Cardiovasc Diabetol 2019
43
33

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
33

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
250
33



Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang. Cardiovasc Diabetol 2020
13
33

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
319
33

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
991
33

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
33


Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
233
33

Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Dario Giugliano, Maria Ida Maiorino, Miriam Longo, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito. Endocrine 2019
10
33

Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
D Patoulias, A Katsimardou, M-S Kalogirou, I Zografou, M Toumpourleka, K Imprialos, K Stavropoulos, I Stergiou, C Papadopoulos, M Doumas. Diabetes Metab 2020
1
100

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Diabetes care--improvement through measurement.
Björn Eliasson, Soffia Gudbjörnsdottir. Diabetes Res Clin Pract 2014
77
33



Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, Kenneth Mangion, Giles Roditi, Ross T Campbell, Colin Berry, Victor Chong, Liz Coyle, Kieran F Docherty,[...]. Circulation 2021
37
33

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
Elvira D'Andrea, Aaron S Kesselheim, Jessica M Franklin, Emily H Jung, Spencer Phillips Hey, Elisabetta Patorno. Cardiovasc Diabetol 2020
5
33

Review of 103 Swedish Healthcare Quality Registries.
L Emilsson, B Lindahl, M Köster, M Lambe, J F Ludvigsson. J Intern Med 2015
196
33

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Melanie J Davies, Richard Bergenstal, Bruce Bode, Robert F Kushner, Andrew Lewin, Trine Vang Skjøth, Arne Haahr Andreasen, Christine Bjørn Jensen, Ralph A DeFronzo. JAMA 2015
344
33

SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Matthew A Cavender, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, John P Wilding, Kamlesh Khunti, Alex Z Fu, Johan Bodegård, Betina T Blak, Eric Wittbrodt,[...]. J Am Coll Cardiol 2018
59
33

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
3
33

Avoidable flaws in observational analyses: an application to statins and cancer.
Barbra A Dickerman, Xabier García-Albéniz, Roger W Logan, Spiros Denaxas, Miguel A Hernán. Nat Med 2019
55
33

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
136
33

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
812
33


Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Peter Ueda, Henrik Svanström, Mads Melbye, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Björn Pasternak. BMJ 2018
130
33


Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.
Michael Fralick, Seoyoung C Kim, Sebastian Schneeweiss, Brendan M Everett, Robert J Glynn, Elisabetta Patorno. BMJ 2020
8
33

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
731
33

Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Aaron Y Kluger, Kristen M Tecson, Andy Y Lee, Edgar V Lerma, Janani Rangaswami, Norman E Lepor, Michael E Cobble, Peter A McCullough. Cardiovasc Diabetol 2019
56
33

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
Takehiro Kawata, Takashi Iizuka, Kotaro Iemitsu, Masahiro Takihata, Masahiko Takai, Shigeru Nakajima, Nobuaki Minami, Shinichi Umezawa, Akira Kanamori, Hiroshi Takeda,[...]. J Clin Med Res 2017
9
33

Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.
Xiaoling Cai, Liwei Ji, Yifei Chen, Wenjia Yang, Lingli Zhou, Xueyao Han, Simin Zhang, Linong Ji. J Diabetes Investig 2017
27
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.